Hitzer Patrick, Bäuerle Tim, Drieschner Tobias, Ostertag Edwin, Paulsen Katharina, van Lishaut Holger, Lorenz Günter, Rebner Karsten
Process Analysis and Technology (PA&T), Faculty Applied Chemistry, Reutlingen University, Alteburgstr. 150, 72762, Reutlingen, Germany.
AbbVie Deutschland GmbH & Co.KG, Knollstr. 50, 67061, Ludwigshafen, Germany.
Anal Bioanal Chem. 2017 Jul;409(18):4321-4333. doi: 10.1007/s00216-017-0292-z. Epub 2017 Mar 25.
Newly developed active pharmaceutical ingredients (APIs) are often poorly soluble in water. As a result the bioavailability of the API in the human body is reduced. One approach to overcome this restriction is the formulation of amorphous solid dispersions (ASDs), e.g., by hot-melt extrusion (HME). Thus, the poorly soluble crystalline form of the API is transferred into a more soluble amorphous form. To reach this aim in HME, the APIs are embedded in a polymer matrix. The resulting amorphous solid dispersions may contain small amounts of residual crystallinity and have the tendency to recrystallize. For the controlled release of the API in the final drug product the amount of crystallinity has to be known. This review assesses the available analytical methods that have been recently used for the characterization of ASDs and the quantification of crystalline API content. Well-established techniques like near- and mid-infrared spectroscopy (NIR and MIR, respectively), Raman spectroscopy, and emerging ones like UV/VIS, terahertz, and ultrasonic spectroscopy are considered in detail. Furthermore, their advantages and limitations are discussed with regard to general practical applicability as process analytical technology (PAT) tools in industrial manufacturing. The review focuses on spectroscopic methods which have been proven as most suitable for in-line and on-line process analytics. Further aspects are spectroscopic techniques that have been or could be integrated into an extruder.
新开发的活性药物成分(API)通常在水中溶解度很差。因此,API在人体中的生物利用度会降低。克服这一限制的一种方法是制备无定形固体分散体(ASD),例如通过热熔挤出(HME)。这样,难溶性的API结晶形式就转变为更易溶的无定形形式。为了在热熔挤出过程中实现这一目标,API被嵌入聚合物基质中。所得的无定形固体分散体可能含有少量残余结晶度,并且有重结晶的趋势。为了在最终药物产品中实现API的控释,必须了解结晶度的含量。本综述评估了最近用于表征无定形固体分散体和定量结晶API含量的现有分析方法。详细考虑了近红外光谱和中红外光谱(分别为NIR和MIR)、拉曼光谱等成熟技术,以及紫外可见光谱、太赫兹光谱和超声光谱等新兴技术。此外,还讨论了它们作为工业制造中的过程分析技术(PAT)工具在一般实际应用中的优点和局限性。本综述重点关注已被证明最适合在线和在线过程分析的光谱方法。其他方面是已经或可以集成到挤出机中的光谱技术。